Tenofovir use is associated with a decreased risk of hepatocellular carcinoma among men with HIV irrespective of coinfection status

BACKGROUND & AIMS: Tenofovir is recommended as part of the first-line antiretroviral therapy (ART) to treat people living with HIV (PLWH) with HBV coinfection. However, the effects of tenofovir-containing ART on hepatocellular carcinoma (HCC) risk among PLWH with/without chronic hepatitis virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Mei-Hsuan, Wu, Ping-Feng, Chen, Tzu-I, Chan, Chi, Lin, Hsi-Hsun, Huang, Yi-Hsiang, Chen, Hsuan-Yu, Lin, Yi-Tsung, Chen, Chien-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852951/
https://www.ncbi.nlm.nih.gov/pubmed/36686591
http://dx.doi.org/10.1016/j.jhepr.2022.100634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9852951/
https://www.ncbi.nlm.nih.gov/pubmed/36686591
http://dx.doi.org/10.1016/j.jhepr.2022.100634

Ejemplares similares